FDC346.40

FDC Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersIOLCPMOREPENLABINNOVACAPORCHPHARMASENORESGUJTHEMRPGLIFESANOFIMcap ₹5,640 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations486.4458.2462.0638.3513.8464.1491.9648.4473.0464.7584.8667.7
Other Income27.224.720.328.434.718.816.135.520.620.849.947.7
Total Income513.6482.9482.3666.7548.5482.9508.0683.9493.7485.5634.7715.4
Expenses
+ Cost of Materials Consumed136.6142.4149.8135.7140.0148.9156.6178.3140.7108.5148.9144.5
+ Purchases of Stock-in-Trade31.727.434.836.232.626.032.634.333.917.641.821.5
+ Changes in Inventories1.1-19.1-31.259.110.4-14.0-27.9-3.4-30.025.514.947.7
+ Employee Benefit Expense100.4103.5103.2117.2125.0118.6121.6132.4120.8120.1109.3135.2
+ Finance Costs1.11.01.01.31.10.91.21.21.21.11.50.8
+ Depreciation & Amortisation9.910.010.411.013.813.415.614.915.214.814.415.1
+ Other Expenses140.2120.1149.1143.5135.7137.9155.0166.5173.9140.8163.5175.9
Total Expenses420.9385.3417.1504.0458.6431.8454.7524.1455.6428.3494.3540.7
EBITDA76.483.856.3146.670.246.754.0140.333.852.3106.4143.0
EBIT66.573.845.9135.656.433.338.4125.418.637.592.0127.9
Profit
PBT before Exceptional Items92.797.565.2162.790.051.253.3159.838.157.2140.4174.7
+ Exceptional Items0.00.00.00.00.00.00.00.00.0-20.80.00.0
Pretax Income92.797.565.2162.790.051.253.3159.838.136.4140.4174.7
+ Current Tax23.820.713.636.720.013.615.735.010.99.531.139.8
+ Deferred Tax-0.9-2.35.47.0-2.10.6-1.03.4-1.1-1.45.92.4
Tax Expense22.918.418.943.718.014.114.638.49.78.137.042.2
Net Income69.879.246.3119.072.037.038.7121.428.428.3103.4132.5
+ Net Income — Continuing Ops69.879.246.3119.072.037.038.7121.428.428.3103.4132.5
+ Other Comprehensive Income1.10.5-1.00.61.40.4-3.8-0.61.20.72.71.0
Total Comprehensive Income70.979.745.3119.673.437.534.8120.729.629.0106.1133.5
Net Income to Common69.879.246.3119.673.437.5121.4132.5
Minority Interest-0.0-0.10.00.00.00.00.00.0
Per Share
Basic EPS4.224.862.847.314.432.282.387.451.751.746.358.14
Diluted EPS4.224.862.847.310.002.282.387.451.751.746.358.14
Other Comprehensive Income — detail
+ Other Comprehensive Income-3.8-0.61.20.72.71.0
+ Items NOT to be Reclassified to P&L0.00.1-0.10.30.00.0-3.0-1.1-0.40.32.20.2
+ Tax on Items NOT to be Reclassified-0.5-0.3-0.20.00.50.0
+ Tax on Items NOT to be Reclassified — alt tag0.00.0-0.10.00.00.0
+ Items to be Reclassified to P&L1.10.5-1.00.31.30.4-1.30.20.50.90.9
+ Tax on Items to be Reclassified0.00.0-1.40.00.00.0
Comprehensive Income — Owners of Parent70.879.945.3119.673.437.5120.729.0133.5
Comprehensive Income — Non-controlling Interests0.1-0.30.00.00.00.00.029.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations4.224.862.847.314.432.282.387.451.751.746.358.14
Diluted EPS — Continuing Operations4.224.862.847.310.002.282.387.451.751.746.358.14
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit317.0307.4308.7407.3330.8303.2330.5439.2328.5313.2379.2454.1
Gross Margin %65.1767.0966.8163.8164.3865.3367.2067.7369.4467.3964.8468.00
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)92.797.565.2162.790.051.253.3159.838.157.2140.4174.7
− Exceptional Items (reconciliation)0.00.00.00.00.00.00.00.00.0-20.80.00.0
Net Income Adj (tax-effected)69.879.246.3119.072.037.038.7121.428.444.5103.4132.5
EPS Adj4.224.862.847.314.432.282.387.451.752.736.358.14
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.001.001.001.001.001.001.001.001.00
Paid Up Equity Capital16.316.316.316.316.316.316.316.316.316.316.316.3
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.